Genmab (GE91) Price & Analysis
GE91 Stock Chart & Stats
- Day’s Range
- EUR 50.00 - EUR 50.00
- 52-Week Range
- EUR 20.20 - EUR 51.00
- Previous Close
- EUR 50.00
- Volume
- 0
- Average Volume (3M)
- 35
- Market Cap
- EUR 31.15B
- Enterprise Value
- EUR 20.72B
- Total Cash (Recent Filing)
- EUR 1.50B
- Total Debt (Recent Filing)
- EUR 5.27B
- Price to Earnings (P/E)
- 45.6
- Beta
- 0.70
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- 0.31
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Growth And Operating Leverage
Strong commercial momentum across EPKINLY, DARZALEX and the broader portfolio is supporting a meaningfully higher revenue outlook. The limited increase in planned operating expenses relative to sales growth also indicates potential operating leverage, strengthening the durability of future profit expansion.
Late-stage Pipeline Validation
Positive Phase 3 evidence for petosemtamab materially strengthens Genmab’s oncology pipeline and supports a potential future commercial product beyond its existing portfolio. Meeting both survival and response endpoints improves the asset’s regulatory and strategic relevance over the next several years.
Recurring Royalty-based Revenue
Royalties on a globally commercialized therapy provide Genmab with recurring, economically attractive revenue without requiring it to fund every aspect of worldwide commercialization. DARZALEX’s scale can support cash generation and help finance internal development and launches across the pipeline.
Bears Say
Material Margin Compression
The sharp decline in operating and net margins shows that recent revenue growth is not translating proportionally into earnings. If lower profitability persists while Genmab continues investing in launches and research, internal funding capacity and the pace of earnings compounding could remain constrained.
Higher Leverage And Weaker Cash Momentum
Debt close to equity represents a substantial change from Genmab’s historically low leverage and reduces financial flexibility. Combined with shrinking free cash flow and weaker cash conversion, the higher balance-sheet burden could limit the company’s ability to absorb execution setbacks or sustain aggressive investment internally.
Competitive And Regulatory Development Risk
Competition from multiple bispecifics, targeted agents and other oncology technologies may make it harder for Genmab’s pipeline products to secure share or premium positioning. Regulatory uncertainty around confirmatory trials adds further risk to approval timing, development plans and the durability of projected growth.
GE91 FAQ
What was Genmab’s price range in the past 12 months?
What is Genmab’s market cap?
When is Genmab’s upcoming earnings report date?
How were Genmab’s earnings last quarter?
Is Genmab overvalued?
Does Genmab pay dividends?
What is Genmab’s EPS estimate?
How many shares outstanding does Genmab have?
What happened to Genmab’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Genmab?
What is the TipRanks Smart Score and how is it calculated?
Genmab Stock Smart Score
Company Description
Genmab
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jan van de Winkel
- Employees
- 3,119
- Website
- www.genmab.com
- Address
- Carl Jacobsens Vej 30, Copenhagen, CD, 2500, DK
Genmab (GE91) Earnings & Revenues
GE91 Company Deck
GE91 Earnings Call
Earnings Call SentimentPositive
Genmab presented a strongly positive commercial and financial performance in H1 2026 — double-digit revenue and operating profit growth, upgraded full-year guidance, robust Epkinly momentum, meaningful product sales (DARZALEX, EPKINLY, TIVDAK), and multiple late-stage clinical advances including a positive Phase III PFS readout and new Phase III initiations. The company also acknowledged execution uncertainties: several data readouts remain event-driven or immature (OS not yet mature), competition across key indications is intensifying, some trial timing/readout clarifications raised investor questions, and integration/IP/tax factors introduce near-term modeling uncertainty. On balance the operational and financial momentum and near-term catalyst calendar outweigh the challenges, supporting a constructive outlook.
View all DE:GE91 earnings summariesGE91 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |